ASP Isotopes Inc. — Company profile
Materials · Chemicals · United States
Last price 2.02 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 309.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
Details
| Name | ASP Isotopes Inc. |
| Sector | Materials |
| Industry | Specialty Chemicals |
| Employees | 271 |
| Founded | 2021 |
| Ipo Date | 2022-11-10 |
| Ceo | Paul Elliot Mann |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 4.00 |
| Isin | US00218A1051 |
| Cusip | 00218A105 |
| Cik | 1921865 |
| Sic | 2890 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Gerdus Kemp M.D., Ph.D. | Medical Director and Chief Executive Officer of Pet Labs |
| Paul Elliot Mann C.F.A. | Executive Chairman and Chief Executive Officer |
| Heather Kiessling | Chief Financial Officer |
| Robert Ainscow | Chief Operating Officer |
| Nicholas Michael Mitchell | Co-Chief Operating Officer |
| Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D. | Chief Technology Officer |
| Shveta Vilas Dighe | Head of Investor Relations |
| Donald George Ainscow | EVice President, General Counsel and Secretary |
| Stefano Marani | President of Electronics and Space |
Contact
| Address | 2200 Ross Avenue, Suite 4575E, Dallas, Texas 75201, United States |
| Phone | 214 432 8219 |
| Website | https://aspisotopes.com |